A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cause the cells to grow uncontrollably. Although current treatments may be effective, tumours may stop responding over time, highlighting the need for newer options. This study is evaluating velzatinib (GSK6042981) in participants with newly diagnosed GIST that has spread or cannot be surgically removed. Velzatinib will be compared with imatinib, the standard treatment, to assess whether it can delay disease worsening and is safe and well tolerated.
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
扩展访问
联系人和位置
学习联系方式
- 姓名:US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
研究联系人备份
- 姓名:EU GSK Clinical Trials Call Center
- 电话号码:+44 (0) 20 89904466
- 邮箱:GSKClinicalSupportHD@gsk.com
学习地点
-
-
-
Beijing、中国、100141
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Jian Li
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Chengdu、中国、610041
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Bo Zhang
-
Guangzhou、中国、510060
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Haibo Qiu
-
Guangzhou、中国、510655
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Yanhong Deng
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Guangzhou、中国、510080
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Xinhua Zhang
-
Hangzhou、中国、310016
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Yu Zheng
-
Jinan、中国、250021
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Lei Cong
-
Nanjing、中国
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Hao Xu
-
Shanghai、中国、200000
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ye Zhou
-
Shanghai、中国、20001
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Ming Wang
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Wuhan、中国、430022
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kai-Xiong Tao
-
Zhengzhou、中国、450052
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Yang Fu
-
-
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Albiruni Abdul Razak
-
-
Quebec
-
Montreal、Quebec、加拿大、H3A 1A1
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Jonathan Noujaim
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Changhua、台湾、500
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ruo-Han TSENG
-
Taichung、台湾、404
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Li-Yuan Bai
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Taipei、台湾、10002
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kun-Huei Yeh
-
Taipei、台湾、112
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Chueh-Chuan Yen
-
Taoyuan、台湾、33305
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Chun-Nan Yeh
-
-
-
-
-
Barretos、巴西、14784-400
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Arinilda Bragagnoli
-
Florianópolis、巴西、88034-000
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ana Paula Stramosk
-
Natal、巴西、59075-740
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Sulene Oliveira
-
Porto Alegre、巴西、90020-090
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Andreas Lutz
-
Vitória、巴西、29043-260
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- GLAUCIO BERTOLLO
-
-
Piauí
-
Teresina、Piauí、巴西、64002-530
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Welligton Figueiredo
-
-
-
-
-
Thessaloniki、希腊、54639
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Grigorios Rallis
-
Thessaloniki、希腊、55535
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ioannis Boukovinas
-
-
Attica
-
Chaïdári、Attica、希腊、124 62
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Anastasios Kyriazoglou
-
-
Crete
-
Heraklion、Crete、希腊、700 13
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ioannis Souglakos
-
-
-
-
-
Milan、意大利、20133
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Elena Rosa Fumagalli
-
Milan、意大利、20141
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Roberta Giovanna Sanfilippo
-
Palermo、意大利
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Giuseppe Badalamenti
-
Roma、意大利、00128
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Bruno Vincenzi
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Oslo、挪威、0379
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kjetil Boye
-
-
-
-
-
Ehime、日本、791-0280
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Tomohiro Nishina
-
Fukuoka、日本、812-8582
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Eiji Oki
-
Gifu、日本、501-1194
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Nobuhisa Matsuhashi
-
Hokkaido、日本、060-8648
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Yoshito Komatsu
-
Kanagawa、日本、241-8515
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Hiroki Osumi
-
Osaka、日本、565-0871
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Yukinori Kurokawa
-
Tokyo、日本、104-0045
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Hidekazu Hirano
-
Tokyo、日本、135-8550
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Masato Ozaka
-
Toyama、日本、930-0194
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Takayuki Ando
-
Yamaguchi、日本、755-8505
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Tatsuya Ioka
-
-
-
-
-
Lyon、法国、69373
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Mehdi Brahmi
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Reims、法国、51100
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Olivier Bouché
-
-
-
-
-
Warsaw、波兰、02-781
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Piotr Rutkowski
-
-
-
-
Victoria
-
Melbourne、Victoria、澳大利亚、3004
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- John Zalcberg
-
-
-
-
-
Uppsala、瑞典、SE-751 85
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Sharmineh Moghaddam
-
-
-
-
-
Genolier、瑞士、1272
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Michael Montemurro
-
-
-
-
Arizona
-
Scottsdale、Arizona、美国、85258
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Michael Gordon
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
California
-
San Francisco、California、美国、94158
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Victoria Wang
-
-
Connecticut
-
New Haven、Connecticut、美国、06510-3206
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Philippos Costa
-
-
Maryland
-
Bethesda、Maryland、美国、20817-1802
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ralph Boccia
-
-
Missouri
-
Kansas City、Missouri、美国、64132
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Jaswinder Singh
-
-
Nebraska
-
Omaha、Nebraska、美国、68130-2042
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Kirsten Leu
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Ciara Kelly
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Juneko Grilley-Olson
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
Ohio
-
Canton、Ohio、美国、44718
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Nashat Gabrail
-
-
Tennessee
-
Knoxville、Tennessee、美国、37920
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Saikrishna Gadde
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
Texas
-
Houston、Texas、美国、77030
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Neeta Somaiah
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
Washington
-
Seattle、Washington、美国、98109-4405
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Min Park
-
-
-
-
-
Helsinki、芬兰、00029
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Sari Jaamaa
-
-
-
-
-
London、英国、SW3 6JJ
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Robin Jones
-
London、英国、NW1 2PG
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Vasilios Karavasilis
-
Newcastle upon Tyne、英国、NE7 7DN
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Anna Stansfeld
-
Sheffield、英国、S10 2SJ
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Robin Young
-
-
Greater Manchester
-
Manchester、Greater Manchester、英国、M20 4BX
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Alexander Lee
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Nijmegen、荷兰、6525GA
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ingrid Desar
-
-
South Holland
-
Leiden、South Holland、荷兰、2333 ZA
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Hans Gelderblom
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
BaracaldoVizcaya、西班牙、48903
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Alberto Muñoz Llarena
-
Barcelona、西班牙、8025
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Raul Teres Lleida
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
Madrid、西班牙、28046
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Virginia Martinez Marin
-
Madrid、西班牙、28034
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- María Ángeles Vaz Salgado
-
Madrid、西班牙、28040
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Nadia Hindi Muñiz
-
Madrid、西班牙、28041
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Aránzazu Manzano Fernández
-
Oviedo、西班牙、33011
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Maria del Pilar Solis Hernandez
-
Seville、西班牙、41013
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Irene Carrasco García
-
Valencia、西班牙、46009
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Hector Augusto Aguilar Andino
-
Zaragoza、西班牙、50009
- 招聘中
- GSK Investigational Site
-
首席研究员:
- Javier Martínez Trufero
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
-
-
-
-
Buenos Aires、阿根廷、1425
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Mariano Dioca
-
Capital Federal、阿根廷、C1426ANZ
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Yanina Pfluger
-
Ciudad Autonoma de Buenos Aire、阿根廷、C1414DRK
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Guillermo Mendez
-
Ciudad Autonoma de Buenos Aire、阿根廷、C1431FWO
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Julieta Grasselli
-
Ciudad autOnoma de Bueno、阿根廷、C1419AHN
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Samanta Straminsky
-
San Miguel de Tucumán、阿根廷、T4000IHE
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ruben Segovia
-
-
-
-
-
Seongnam-si Gyeonggi-do、韩国、13620
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Ji-Won Kim
-
Seoul、韩国、03080
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Do-youn Oh
-
Seoul、韩国、03722
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Minkyu Jung
-
Seoul、韩国、138-736
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Min-Hee Ryu
-
Seoul、韩国、03181
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Dong-Hoe Koo
-
Suwon Kyunggi-do、韩国、16499
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Tae Hwan Kim
-
-
Seoul Teugbyeolsi
-
Seoul、Seoul Teugbyeolsi、韩国、06351
- 招聘中
- GSK Investigational Site
-
接触:
- US GSK Clinical Trials Call Center
- 电话号码:877-379-3718
- 邮箱:GSKClinicalSupportHD@gsk.com
-
接触:
- EU GSK Clinical Trials Call Centre
- 电话号码:+44 (0) 20 8990 4466
- 邮箱:GSKClinicalSupportHD@gsk.com
-
首席研究员:
- Jungyong Hong
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed consent form (ICF).
-
Has histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.
-
Has not received prior systemic therapy for their metastatic and/or surgically unresectable GIST.
-
Tumor tissue must be provided to the central laboratory. Tumor tissues may be archival (preferred) or obtained from a fresh biopsy acquired for standard of care (biopsies must be collected before randomization).
-
Participants must have ≥1 target lesion (TL).
-
All participants must use adequate contraception according to local regulations throughout the study and for a specified period after the last dose of study medication (at least 30 days for velzatinib/imatinib, or 15 days for imatinib only, as applicable, or longer if local regulations specify).
-
Male participants must either be abstinent or use a male condom (with a recommendation for their female partner to use highly effective contraception). They must also refrain from donating semen.
-
Female participants must not be pregnant or breastfeeding.
- Those of non-childbearing potential are eligible without additional contraception.
- Those of childbearing potential must use an acceptable, highly effective contraceptive method and have a negative pregnancy test before starting the study. The investigator will assess their pregnancy risk.
-
Is capable of giving signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol.
-
Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1.
-
Has adequate organ function.
Exclusion Criteria:
-
Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas [e.g., breast, cervix, bladder] that have been resected with no evidence of metastatic disease.
-
Has any clinically significant gastrointestinal abnormalities that may alter absorption, e.g., malabsorption syndrome or major resection of the stomach and/or bowels.
-
Has had any major surgery (minor surgical procedures such as central venous catheter placement and tumor needle biopsy are not considered major surgical procedures) within 14 days of the first dose of study treatment or participants who have not fully recovered from surgery.
-
Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. Participants with a history of autologous stem cell transplant are eligible for study participation provided the following eligibility criteria are met: a) transplant was [>100 days] prior to screening, and b) the participant has no active infection(s) at the time of screening.
-
Has known allergy or hypersensitivity to velzatinib or imatinib, in the opinion of the investigator or medical monitor, contraindicates participation in the study.
-
Has a history within 6 months prior of clinically significant or uncontrolled cardiac disease, unstable angina, acute myocardial infarction, New York Heart Association Class III or IV congestive heart failure [New York Heart Association,1994], or clinically significant arrhythmia not controlled by standard of care therapy, ventricular arrhythmia, cerebrovascular accident or transient ischemic attack and uncontrolled hypertension.
-
Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed [e.g., evidence of new or enlarging brain metastasis or new neurologic symptoms attributable to brain/CNS metastases]. Participants with previously treated and clinically stable brain/CNS metastases and who have completed all corticosteroid therapy for ≥2 weeks before randomization are not excluded from participation
-
Has ongoing adverse reaction(s) from prior therapy that has (have) not recovered to ≤Grade 1 or to the baseline status preceding prior therapy, (excluding e.g., alopecia, hearing loss, vitiligo, endocrinopathy managed with replacement therapy, and Grade 2 neuropathy) or that the investigator, with the agreement of the sponsor, considers to be not clinically relevant for the tolerability of study intervention in the current clinical study.
-
Has any active renal condition (e.g., infection, requirement for dialysis, or any other significant renal condition that could affect the participant's safety).
-
Has any serious and/or unstable medical or psychiatric disorder or other condition(s) (including laboratory assessment abnormalities) that could interfere with the participant's safety, obtainment of informed consent, or compliance to the study procedures.
-
Has received radiotherapy within 14 days prior to first dose of study treatment.
-
Has received any live vaccine within 30 days of randomization. Vaccination against Coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms (e.g., Emergency Use Authorization, Conditional Marketing Authorization, or Marketing Authorization Application) are not exclusionary.
-
Has received any transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including Granulocyte colony-stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 14 days before randomization.
-
Is currently enrolled or has participated in any other clinical study involving an investigational study intervention or any other type of medical research before signing ICF.
-
Has a positive drug/alcohol screening assessment.
-
Has a known Human immunodeficiency virus (HIV) infection and meets at least one of the following criteria:
- Has documented evidence of plasma HIV-1 ribonucleic acid (RNA) ≥50 c/mL within 3 months prior to or at screening. In the 3 to 12 months prior to screening, plasma HIV 1 RNA levels consistently <50 c/mL are required for enrollment; if multiple instances of plasma HIV-1 RNA values ≥50 c/mL occurred in the 3 to 12 months prior to screening, the participant is not eligible for enrollment unless, per the investigator's assessment, the elevations were neither persistent nor associated with antiretroviral resistance; OR
- Has not had CD4 cell counts measured in the past 12 months (i.e., at least two separate measurements taken a minimum of 28 days apart, one of which must be conducted at screening); OR
- Has had any CD4 cell count values ≤200 cells/mm3 in the past 12 months; OR
- Has had one or more changes in their combination antiretroviral therapy regimen (except for switches as allowed per details provided in protocol) or has received an antiretroviral therapy regimen that is inconsistent with locally recommended guidelines during the 3 months prior to screening; OR
- Has a history of HIV-associated non-Hodgkin lymphoma within 5 years prior to screening or a history of HIV-associated invasive cervical cancer; OR
- Has received treatment with an HIV 1 immunotherapeutic vaccine within 90 days of screening.
-
Is pregnant or breastfeeding.
-
Is unable to adhere to the protocol, including requirements for the Follow-up Period of the study.
-
Has an alanine aminotransferase (ALT) value >2.5x upper limit of normal (ULN) or (for participants with documented liver metastases/tumor infiltration) has an ALT value >5x ULN
-
Has a total bilirubin value >1.5x ULN.
-
Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice.
-
Evidence of chronic hepatitis B virus (HBV) infection with detectable viral load despite antiviral therapy with high resistance barrier.
-
12-lead electrocardiogram (ECG) demonstrating mean QT interval corrected (QTc) corrected by Fridericia's formula >480msec at screening or history of long QT syndrome.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:伊马替尼
|
Imatinib will be administered
其他名称:
|
|
实验性的:Velzatinib
|
Velzatinib will be administered
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-Free Survival (PFS) as assessed by Blinded independent central review (BICR)
大体时间:Up to approximately 74 months
|
PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 74 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of participants with Treatment-emergent adverse event (TEAEs) and serious adverse event (SAEs) by severity
大体时间:Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Number of participants with TEAEs/SAEs leading to dose reductions, interruptions and treatment discontinuation
大体时间:Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Number of participants with clinically significant changes in vital signs, electrocardiograms, and clinical laboratory parameters
大体时间:Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Plasma concentration of velzatinib
大体时间:Up to approximately 75 months
|
Up to approximately 75 months
|
|
|
Confirmed Objective Response Rate (ORR) as assessed by BICR
大体时间:Up to approximately 75 months
|
Confirmed ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) per response criteria. |
Up to approximately 75 months
|
|
Overall survival (OS)
大体时间:Up to approximately 75 months
|
OS is defined as the time from the date of randomization to the date of death due to any cause. |
Up to approximately 75 months
|
|
Confirmed ORR as assessed by Investigator assessment
大体时间:Up to approximately 75 months
|
Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR per response criteria. |
Up to approximately 75 months
|
|
Time from initial study randomization to second disease progression or death (PFS2)
大体时间:Up to approximately 75 months
|
PFS2 is defined as the time from initial study randomization to second disease progression or death after starting the next line of treatment. |
Up to approximately 75 months
|
|
PFS as assessed by Investigator assessment
大体时间:Up to approximately 75 months
|
PFS is defined as time from the date of randomization to the date of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 75 months
|
|
Time to Response (TTR)
大体时间:Up to approximately 75 months
|
TTR as assessed by BICR and investigator, is defined as time from randomization until the first documented PR or CR that was subsequently confirmed. |
Up to approximately 75 months
|
|
Duration of Response (DOR)
大体时间:Up to approximately 75 months
|
DOR as assessed by BICR and investigator, is defined as time from the first documented PR or CR that was subsequently confirmed until the first documented PD or death due to any cause. |
Up to approximately 75 months
|
|
Time to Second Subsequent Therapy (TSST)
大体时间:Up to approximately 75 months
|
TSST is defined as the time from the date of randomization to the earliest date of second subsequent therapy or death due to any cause. |
Up to approximately 75 months
|
|
Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) score
大体时间:Up to approximately 75 months
|
The EORTC QLQ-C30 includes 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. These include functional scales, symptom scales, global health status scale, and single item scales. Scores are averaged and transformed to 0 to 100. Higher scores indicate greater functioning, better global health status, or more severe symptoms |
Up to approximately 75 months
|
|
Time to confirmed deterioration (TTCD) of EORTC QLQ-C30
大体时间:Up to approximately 75 months
|
TTCD is defined as the time from the date of randomization to the first confirmed clinically meaningful deterioration on the Physical & Role Functioning & Global Health Status/QoL scales of the EORTC QLQ-C30. |
Up to approximately 75 months
|
|
Number of participants with symptomatic AEs by severity as measured by patient-reported outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE)
大体时间:Up to approximately 75 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicities in participants in cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to approximately 75 months
|
|
Number of participants with bothersome AEs/tolerability as measured by the Functional Assessment of Cancer Therapy - General (FACT-GP5)
大体时间:Up to approximately 75 months
|
The FACT GP5 is an assessment focused on the overall side effects impact to inform the tolerability of a treatment. The FACT GP5 ("I am bothered by side effects of treatment") responses are given on a 5-point Likert type scale. The response scale ranges from 0 (Not at all) to 4 (Very much). Higher scores indicate a higher degree of AE bother. |
Up to approximately 75 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- 306293
- 2025-524934-24 (其他标识符:EU CT Number)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.